AGEX THERAPEUTICS INC (AGE) Stock Fundamental Analysis

USA • NYSE Arca • NYSEARCA:AGE • US00848H2076

11.1 USD
-1.5 (-11.9%)
Last: Mar 26, 2024, 08:04 PM
Fundamental Rating

1

Taking everything into account, AGE scores 1 out of 10 in our fundamental rating. AGE was compared to 525 industry peers in the Biotechnology industry. AGE has a bad profitability rating. Also its financial health evaluation is rather negative. AGE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year AGE has reported negative net income.
  • AGE had a negative operating cash flow in the past year.
AGE Yearly Net Income VS EBIT VS OCF VS FCFAGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -5M -10M -15M

1.2 Ratios

  • The Return On Assets of AGE (-115.07%) is worse than 82.31% of its industry peers.
  • With a Return On Equity value of -166.86%, AGE is not doing good in the industry: 69.05% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -115.07%
ROE -166.86%
ROIC N/A
ROA(3y)-291.66%
ROA(5y)-221.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AGE Yearly ROA, ROE, ROICAGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400 600 800

1.3 Margins

  • Looking at the Gross Margin, with a value of 50.00%, AGE belongs to the top of the industry, outperforming 80.27% of the companies in the same industry.
  • AGE's Gross Margin has declined in the last couple of years.
  • AGE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.98%
GM growth 5Y-5.52%
AGE Yearly Profit, Operating, Gross MarginsAGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -10K -20K -30K

More info and screens

2

2. Health

2.1 Basic Checks

  • AGE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AGE remains at a similar level compared to 1 year ago.
  • Compared to 1 year ago, AGE has a worse debt to assets ratio.
AGE Yearly Shares OutstandingAGE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
AGE Yearly Total Debt VS Total AssetsAGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M

2.2 Solvency

  • AGE has an Altman-Z score of 49.65. This indicates that AGE is financially healthy and has little risk of bankruptcy at the moment.
  • AGE's Altman-Z score of 49.65 is amongst the best of the industry. AGE outperforms 96.94% of its industry peers.
  • A Debt/Equity ratio of 0.08 indicates that AGE is not too dependend on debt financing.
  • The Debt to Equity ratio of AGE (0.08) is worse than 64.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 49.65
ROIC/WACCN/A
WACC9.52%
AGE Yearly LT Debt VS Equity VS FCFAGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 10M -10M -20M

2.3 Liquidity

  • AGE has a Current Ratio of 0.36. This is a bad value and indicates that AGE is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.36, AGE is doing worse than 96.26% of the companies in the same industry.
  • AGE has a Quick Ratio of 0.36. This is a bad value and indicates that AGE is not financially healthy enough and could expect problems in meeting its short term obligations.
  • AGE has a Quick ratio of 0.36. This is amonst the worse of the industry: AGE underperforms 96.09% of its industry peers.
Industry RankSector Rank
Current Ratio 0.36
Quick Ratio 0.36
AGE Yearly Current Assets VS Current LiabilitesAGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

  • AGE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -42.31%.
  • Looking at the last year, AGE shows a very strong growth in Revenue. The Revenue has grown by 66.67%.
  • The Revenue for AGE have been decreasing by -53.63% on average. This is quite bad
EPS 1Y (TTM)-42.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
Revenue 1Y (TTM)66.67%
Revenue growth 3Y-74.12%
Revenue growth 5Y-53.63%
Sales Q2Q%600%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AGE Yearly Revenue VS EstimatesAGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • AGE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGE Price Earnings VS Forward Price EarningsAGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGE Per share dataAGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2 -0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for AGE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGEX THERAPEUTICS INC / AGE FAQ

Can you provide the ChartMill fundamental rating for AGEX THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to AGE.


Can you provide the valuation status for AGEX THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to AGEX THERAPEUTICS INC (AGE). This can be considered as Overvalued.


What is the profitability of AGE stock?

AGEX THERAPEUTICS INC (AGE) has a profitability rating of 1 / 10.


How financially healthy is AGEX THERAPEUTICS INC?

The financial health rating of AGEX THERAPEUTICS INC (AGE) is 2 / 10.